Advertisement

Topics

Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma

08:04 EST 11 Feb 2019 | FinanzNachrichten

Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that its collaborator, Takeda Pharmaceutical Company Limited, received approval from the European Commission to extend the marketing authorizat...

Original Article: Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics Achieves $30 Million Milestone Payment for European Commission Approval of ADCETRIS (Brentuximab Vedotin) in Frontline Hodgkin Lymphoma"

Advertisement
Quick Search
Advertisement
Advertisement